Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
The growing number of infections caused by multidrug-resistant pathogens has prompted a more rational use of available antibiotics given the paucity of new, effective agents. Monte Carlo simulations were utilized to determine the appropriateness of several doripenem dosing regimens based on the probability of attaining the critical drug exposure metric of time that drug concentrations remain above the drug MIC (T>MIC) for 35% (and lower thresholds) of the dosing interval in >80 to 90% of the population (T>MIC 35% target). This exposure level generally correlates with in vivo efficacy for carbapenems. In patients with creatinine clearance of >50 ml/min, a 500-mg dose of doripenem infused over 1 h every 8 h is expected to be effective against bacilli with doripenem MICs of < or =1 microg/ml based on a T>MIC 35% target and MICs of < or =2 microg/ml based on lower targets. A longer, 4-hour infusion time improved target attainment in most cases, such that the T>MIC was adequate for pathogens with doripenem MICs as high as 4 microg/ml. Efficacy is expected for infections caused by pathogens with doripenem MICs of < or =2 microg/ml in patients with moderate renal impairment (creatinine clearance, 30 to 50 ml/min) who receive doripenem at 250 mg infused over 1 h every 8 h and in patients with severe impairment (creatinine clearance between 10 and 29 ml/min) who receive doripenem at 250 mg, infused over 1 h or 4 h, every 12 h. Results of pharmacokinetics/pharmacodynamics (PK/PD) modeling can guide dose optimization, thereby potentially increasing the clinical efficacy of doripenem against serious Gram-negative bacterial infections.
Samtani
Mahesh N
MN
Clinical Pharmacology, Advanced PK/PD Modeling and Simulation, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ 08560, USA.
Flamm
Robert
R
Kaniga
Koné
K
Nandy
Partha
P
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D015780:Carbapenems / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D003404:Creatinine / Q000378:metabolism; D016638:Critical Illness; D000077726:Doripenem; D004334:Drug Administration Schedule; D024901:Drug Resistance, Multiple, Bacterial; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism* / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D006801:Humans; D007262:Infusions, Intravenous; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D009010:Monte Carlo Method
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D003404:Creatinine; D000077726:Doripenem
Curr Opin Crit Care. 2008 Aug;14(4):390-6
18614901
J Clin Pharmacol. 2006 Oct;46(10):1171-8
16988206
J Antimicrob Chemother. 2003 Aug;52(2):229-46
12865398
Intensive Care Med. 1996 May;22(5):387-94
8796388
Curr Med Res Opin. 2008 Jul;24(7):2113-26
18549664
Antimicrob Agents Chemother. 2009 Sep;53(9):3782-92
19581455
Curr Opin Crit Care. 2007 Oct;13(5):598-606
17762242
Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S11-6
19619017
Crit Care. 2008;12 Suppl 4:S2
18495059
Clin Infect Dis. 2007 Feb 1;44(3):357-63
17205441
Clin Infect Dis. 2000 Sep;31 Suppl 4:S131-8
11017862
Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7
16127078
Diagn Microbiol Infect Dis. 2009 Apr;63(4):409-14
19249182
Int J Antimicrob Agents. 2002 Apr;19(4):313-22
11978502
Crit Care Med. 2008 Apr;36(4):1089-96
18379232
Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S28-35
19619019
Nat Rev Microbiol. 2004 Apr;2(4):289-300
15031728
Clin Infect Dis. 2006 Mar 1;42(5):657-68
16447111
Clin Infect Dis. 2005 Jul 15;41(2):139-48
15983908
Clin Ther. 2008 May;30(5):868-83
18555934
Antimicrob Agents Chemother. 2005 Apr;49(4):1337-9
15793108
Drug Saf. 2009;32(9):709-16
19670912
Semin Respir Crit Care Med. 2007 Dec;28(6):579-85
18095221
Pharmacotherapy. 2007 Mar;27(3):333-42
17316145
Chest. 2000 Jul;118(1):146-55
10893372
Diagn Microbiol Infect Dis. 2008 May;61(1):86-95
18385000
Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
9455502
Ann Pharmacother. 2006 Feb;40(2):219-23
16449546
J Infect. 2007 Aug;55(2):111-8
17568680
Postgrad Med. 2008 Sep;120(3 Suppl 1):8-15
18931466
Antimicrob Agents Chemother. 2010 Jun;54(6):2354-9
20385854
Ann Clin Microbiol Antimicrob. 2008 Jan 11;7:1
18190701